For my breast oncology colleagues:

Targeted Oncology· @TargetedOnc · X·2026-10-24 14:52· 22 hours agoScore70

Body

Does KEYNOTE-B49 change your practice?

Would you consider pembrolizumab + chemotherapy in selected CPS ≥10 patients, or wait for stronger evidence of clinical benefit?

How does it fit alongside modern targeted therapies and ADCs?

#ESMO26

52 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage

Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)

https://esmocongress.esmo.org

Source: Targeted Oncology · x.com